The following represents disclosure information provided by authors of this abstract. The ASCO Scientific Program Committee has reviewed all presenting author disclosure reports, identified potential conflicts of interest, and implemented strategies to manage those areas of conflict, where appropriate. All relationships are considered self-held and compensated unless otherwise noted. Employment/Leadership relationships are considered compensated employment unless otherwise noted. L = Leadership, U = Uncompensated, I = Immediate Family Member, B = Both Myself and Immediate Family Member, Inst = My Institution
Toxicity, surgical complications, and short-term mortality in a randomized trial of neoadjuvant cisplatin/5FU versus epirubicin/cisplatin and capecitabine prior to resection of lower esophageal/gastroesophageal junction (GOJ) adenocarcinoma (MRC OEO5, ISRCTN01852072, CRUK 02/010).
David Cunningham
Research Funding - Amgen; AstraZeneca; Celgene; Merck Serono; Novartis; Roche; Sanofi
Derek Alderson
No relevant relationships to disclose
Matthew Guy Nankivell
No relevant relationships to disclose
Sally Patricia Stenning
Research Funding - UK Medical Research Council
Jane M. Blazeby
No relevant relationships to disclose
Michael Griffin
No relevant relationships to disclose
Adrian Crellin
No relevant relationships to disclose
Heike I. Grabsch
Research Funding - CancerResearch UK
Stephen Falk
No relevant relationships to disclose
Alicia Frances Clare Okines
Honoraria - Roche
Other Remuneration - Roche
Claire Robb
No relevant relationships to disclose
Ruth E Langley
Research Funding - UK Medical Research Council